Are IONS insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies IONS leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Stock Ratings / Health Care / IONS / insiders

KNSA (71) AMRX (71) ABVX (54) AXSM (35) ⌘ Pro Terminal →

Ionis Pharmaceuticals Inc. (IONS) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Where is IONS trading relative to its 50-day, 200-day, and 52-week technical levels?

IONS last traded at $43.52 (-1.96% on volume of 1,522,195 shares), positioning the stock -9.26% below its 50-day simple moving average ($47.96) and -34.35% below its 200-day simple moving average ($66.29). Across its 52-week range of $42.08 to $86.74, IONS sits at the 3.2% percentile with a 14-day RSI of 43.6 (NEUTRAL RANGE) and an implied next-earnings move of ±7.2% ($40.39 to $46.65).

$43.52 -1.96% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $43.28

Ionis Pharmaceuticals Inc. (IONS) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $7.23B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IONS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IONS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Ionis Pharmaceuticals Inc. (NASDAQ: IONS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $43.52 (-1.96% 1D, market cap $7.23B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 6/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, IONS ranks #898 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IONS compare to KNSA and AMRX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IONS carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -20.9%. By comparison, KNSA (Kiniksa Pharmaceuticals International plc (Class A)) holds a B- grade (71/100 RQD, P/E 129.9x, ROIC 9.9%, cap $7.25B) and AMRX (Amneal Pharmaceuticals Inc.) posts a B- grade (71/100 RQD, P/E 103.2x, ROIC 14.1%, cap $7.49B). Among the 5-stock peer group, ABVX leads on earnings multiple (32.8x) while AMRX leads on capital efficiency (14.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IONS?

▼

Per IONS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000874015), Ionis Pharmaceuticals Inc. generated $943.7M in revenue (+33.8% YoY), -$381.4M in net income, and -$320.0M in free cash flow against $3.52B in total assets and $1.33B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $43.28 (-0.54%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-14.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IONS)Realized 20D OHLCV Swing Band: ±7.2%

Deterministic 5-Pillar Attribution (26/100 Composite)

🔍 WHY IONS SCORES 26/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+6/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 98.3% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+6/20 pts (23% of score)

Altman Z-Score 1.08 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9

▼ #1 Drag / Risk Factor: Macro Regime Fit4/20 pts (-16 pt drag)

Macro rate sensitivity & RSI-14 (43.6) create a -16 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$42.70+3.7% Next Q

Q2 (-2Q)

Grade E$44.27+1.4% Next Q

Q3 (-1Q)

Grade E$44.90-3.1% Next Q

Current

Grade E$43.52-10.5% Hist 90D α

Trajectory: E (18) → E (26)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IONS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IONS currently carries a cautious 26/100 (E) rating due to Macro Regime Fit (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($47.96) and Max Pain ($45.70) forces dealer call-delta covering toward $91.08.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IONS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “IONS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 26%NO 74%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

IONS Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (IONS)

No recent open-market Form 4 cluster sales or emergency dumps flagged on IONS. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IONS)

✓Walkthrough of IONS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IONS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -42.32%⚡ TESTING RESISTANCE

2026-11-03O $44.39H $44.39L $43.52C $43.52VOL 1.52M

RES: $44.24SUP: $38.24SMA50: $47.96SMA200: $66.29

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IONS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IONS Butterfly Map → + Track IONS →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

15.7%/yr Implied 5Y Growth

vs. +33.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on IONS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IONS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IONS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IONS)

Health Care Rank #898 of 1015 ⚔️ KNSA vs IONS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IONS vs. KNSA, AMRX, ABVX, AXSM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Ionis Pharmaceuticals Inc. (IONS) ranks #898 by composite RQD confidence (26/100, grade E) and #132 by equity capitalization ($7.23B). Within this direct 5-issuer industry benchmark cohort, ABVX leads on earnings valuation at 32.8x trailing P/E, while AMRX leads on capital efficiency and profitability with 14.1% ROIC and 36.9% gross margin. KNSA currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with IONS at 26/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IONS ACTIVE Ionis Pharmaceuticals Inc.	E	26/100	—	96.0%	-20.9%	-1.96%	$7.23B	Benchmark Subject
KNSA Kiniksa Pharmaceuticals International plc (Class A)	B-	71/100	129.9x	88.5%	9.9%	-5.45%	$7.25B	/knsa-vs-ions →
AMRX Amneal Pharmaceuticals Inc.	B-	71/100	103.2x	36.9%	14.1%	+0.75%	$7.49B	/amrx-vs-ions →
ABVX Abivax SA	D+	54/100	32.8x	—	9.9%	-2.77%	$7.56B	/abvx-vs-ions →
AXSM Axsome Therapeutics Inc.	D-	35/100	—	—	-21.9%	+0.68%	$7.57B	/axsm-vs-ions →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000874015 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Ionis Pharmaceuticals Inc. (IONS) reported GAAP revenue of $943.7M (+33.8% vs. FY2024 revenue of $705.1M , and +19.8% cumulative change since FY2023) , GAAP net income of -$381.4M, operating cash flow of -$268.6M, and free cash flow of -$320.0M (+41.4% YoY). On the balance sheet, IONS closed FY2025 with $3.52B in total assets against $1.33B in total debt (Altman Z-Score: 1.08, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$943.7M	-$381.4M	-$268.6M	-$320.0M	$3.52B	$1.33B
FY2024 (FY)	2024-12-31	$705.1M	-$453.9M	-$500.9M	-$546.2M	$3.00B	$1.20B
FY2023 (FY)	2023-12-31	$787.6M	-$366.3M	-$307.5M	-$343.0M	$4.06B	$949.4M

3. IONS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IONS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does IONS compare to KNSA and AMRX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for IONS?

Where is IONS trading relative to its 50-day, 200-day, and 52-week technical levels?

IONS last traded at $43.52 (-1.96% on volume of 1,522,195 shares), positioning the stock -9.26% below its 50-day simple moving average ($47.96) and -34.35% below its 200-day simple moving average ($66.29). Across its 52-week range of $42.08 to $86.74, IONS sits at the 3.2% percentile with a 14-day RSI of 43.6 (NEUTRAL RANGE) and an implied next-earnings move of ±7.2% ($40.39 to $46.65).

Direct Sub-Reports: IONS RQD Cockpit IONS 12M Forecast IONS Earnings & Move IONS Dividends & DRIP IONS Insiders & 13F IONS Whale Options IONS Profit Sankey IONS News & Why

ROARABLE RATING BRIEF • RQD 26/100 (E) ✓ SEC XBRL & RQD VERIFIED

IONS — Ionis Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Ionis Pharmaceuticals Inc. (IONS) earns a live Roarable RQD composite score of 26/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $43.52 (-1.96% 1D, market capitalization $7.23B).

Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -20.9%, gross margin of 96.0%, operating margin of -40.4%, and free cash flow yield of -4.34%.
Whale 13F & Options Flow (5/20) + Insider Conviction (6/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (3/20) + Forensic Balance Sheet (6/20): Incorporates a 1.09x equity beta, Altman Z-Score of 1.08, Piotroski F-Score of 5/9, and Debt/Equity of 2.72x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Ionis Pharmaceuticals Inc. (IONS) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. — for specific product lines, customers, or revenue-generation detail beyond the sector and industry classification.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Ionis Pharmaceuticals Inc. (IONS) reported $943.7M in annual revenue (up from $705.1M in FY2024, +33.8% YoY) and -$381.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($787.6M revenue, -$366.3M net income) through FY2025, IONS scaled operating cash flow to -$268.6M and free cash flow to -$320.0M, backed by $3.52B in total assets against $1.33B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 26/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -4.34% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $42.08 – $86.74 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -40.4% operating margins and a 1.09x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

There are no upstream or downstream links and no proprietary signals recorded for IONS. Sector and industry are Health Care and Biotechnology: Pharmaceutical Preparations. — for specific upstream dependencies, downstream customers, or sector correlation measures. Investors should note that the absence of mapped supply-chain links means second-order ripple effects cannot be assessed from the provided data.

Key Question #1: Can IONS sustain or expand its -40.4% operating margin and -20.9% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $943.7M and free cash flow of -$320.0M, how will capital allocation balance growth reinvestment against $1.33B in total debt?
Key Question #3: How sensitive is IONS's 22.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.09x)?

IONS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Ionis Pharmaceuticals Inc. (IONS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IONS Debate Forum (3) ↓

🔴 RISK WATCH Yahoo Finance • 1d ago

Ionis Pharmaceuticals (IONS) Stock Could Still Trade At A Premium Despite A 46% Slump

Yahoo Finance report covering Ionis Pharmaceuticals Inc. (IONS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Motley Fool • 1d ago

Alnylam vs. Ionis: Here's the Better Bad-News Buy

The Motley Fool report covering Ionis Pharmaceuticals Inc. (IONS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Investing.com • 1d ago

BMO upgrades Ionis Pharmaceuticals stock rating on sHTG opportunity

Investing.com report covering Ionis Pharmaceuticals Inc. (IONS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Ionis Pharmaceuticals: Compelling Long-Term Commercial Upside (NASDAQ:IONS)

Seeking Alpha report covering Ionis Pharmaceuticals Inc. (IONS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Ionis Pharmaceuticals (NasdaqGS:IONS) Stock Forecast & Analyst Predictions

Simply Wall St report covering Ionis Pharmaceuticals Inc. (IONS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Ionis Pharmaceuticals (IONS) After The Pullback Is The Undervalued Narrative Still Intact

Yahoo Finance report covering Ionis Pharmaceuticals Inc. (IONS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 1d ago

Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Ionis Pharmaceuticals (IONS)

The Globe and Mail report covering Ionis Pharmaceuticals Inc. (IONS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 1d ago

InvestingPro Fair Value flagged Ionis stock before 48% plunge By Investing.com

Investing.com report covering Ionis Pharmaceuticals Inc. (IONS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IONS Bull vs. Bear Conversation Board — What's Your Call at $43.52?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IONS 🐻 33% BEARISH CONVICTION

CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $57.45 (+32.0%)

📌 Pinned Debate

A BMO upgrade citing an sHTG opportunity is the only positively flagged catalyst in the news feed.

Long IONS at $43.52 targeting $57.45. A BMO upgrade citing an sHTG opportunity is the only positively flagged catalyst in the news feed.. Institutional whale score is 5/20 and the risk/reward vs. the $42.08 52-week low is skewed heavily in favor of bulls.

RetailWhale_TX 🐂 BULL

@SkepticalCFA Shorting a 5/20 institutional whale-flow stock at $43.52 is dangerous when funds are rotating into Health Care.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $36.56 (-16.0%)

Spot @ $43.52

Negative operating income, negative FCF, and a 1.08 Altman Z-Score point to forensic and liquidity risk.

I respect the product at Ionis Pharmaceuticals Inc., but the stock at $43.52 is a different story. Negative operating income, negative FCF, and a 1.08 Altman Z-Score point to forensic and liquidity risk.. FCF yield is -4.34% and RQD sits at 26/100 (E) — why pay up here when you can wait for next quarter's numbers?